Curt A. Herberts III Sells 15,000 Shares of Sangamo Therapeutics, Inc. (SGMO) Stock
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) VP Curt A. Herberts III sold 15,000 shares of Sangamo Therapeutics stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $17.26, for a total transaction of $258,900.00. Following the completion of the transaction, the vice president now owns 13,015 shares in the company, valued at approximately $224,638.90. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Curt A. Herberts III also recently made the following trade(s):
- On Friday, December 1st, Curt A. Herberts III sold 16,630 shares of Sangamo Therapeutics stock. The stock was sold at an average price of $16.13, for a total transaction of $268,241.90.
Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) traded up $0.45 during trading on Thursday, reaching $17.85. 1,070,000 shares of the company’s stock were exchanged, compared to its average volume of 1,380,000. The company has a market cap of $1,510.00, a price-to-earnings ratio of -25.87 and a beta of 3.15. Sangamo Therapeutics, Inc. has a 1-year low of $3.00 and a 1-year high of $18.69. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64.
SGMO has been the topic of a number of analyst reports. Jefferies Group reiterated a “buy” rating and issued a $18.00 target price on shares of Sangamo Therapeutics in a research report on Friday, October 13th. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Wednesday, November 15th. Piper Jaffray Companies set a $25.00 target price on shares of Sangamo Therapeutics and gave the stock a “buy” rating in a research report on Wednesday. BidaskClub raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, December 29th. Finally, Wedbush reissued a “hold” rating and issued a $6.00 price target on shares of Sangamo Therapeutics in a report on Wednesday, November 15th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $18.83.
A number of institutional investors have recently made changes to their positions in SGMO. Dimensional Fund Advisors LP grew its holdings in Sangamo Therapeutics by 0.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 128,764 shares of the biopharmaceutical company’s stock worth $670,000 after acquiring an additional 513 shares during the last quarter. Aperio Group LLC bought a new stake in Sangamo Therapeutics in the 2nd quarter worth $108,000. Russell Investments Group Ltd. bought a new stake in shares of Sangamo Therapeutics during the 2nd quarter valued at about $203,000. Schwab Charles Investment Management Inc. boosted its stake in shares of Sangamo Therapeutics by 0.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 267,293 shares of the biopharmaceutical company’s stock valued at $2,353,000 after purchasing an additional 1,558 shares in the last quarter. Finally, State of Wisconsin Investment Board bought a new stake in shares of Sangamo Therapeutics during the 2nd quarter valued at about $466,000. 64.33% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Curt A. Herberts III Sells 15,000 Shares of Sangamo Therapeutics, Inc. (SGMO) Stock” was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/04/curt-a-herberts-iii-sells-15000-shares-of-sangamo-therapeutics-inc-sgmo-stock.html.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.